Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815544 | 0.88 | ESR2 (0.53) | ESR2NR1H2ADORA1MAPK1KDM4E | |
| SCHEMBL2923721 | 0.88 | ESR2 (0.53) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL30816257 | 0.82 | HDAC1 (0.45) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL30460276 | 0.81 | ESR2 (0.46) | ESR2NR1H2ADORA1MAPK1KDM4E | |
| SCHEMBL23452601 | 0.81 | ADORA1 (0.46) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL23452343 | 0.80 | ESR2 (0.43) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL15332062 | 0.80 | NR1H2 (0.45) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL31486447 | 0.78 | ESR2 (0.42) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL23452411 | 0.78 | NR1H2 (0.44) | HDAC1ESR2NR1H2ADORA1MAPK1 | |
| SCHEMBL31486492 | 0.77 | NR1H2 (0.43) | HDAC1ESR2NR1H2ADORA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | HDAC1 2690/4885ESR2 3631/4885NR1H2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.